Go Higher: Atai Life Sciences Is Moving the Dial on Psychedelic Medicine Clinical Trial Outcomes

“From the thousand-foot level, there hasn’t been really meaningful advancement in psychiatry, at least in the depression space, since the 1980s with SSRIs,” Glenn Short, PhD, senior vice president of Early Development at atai Life Sciences, told GEN Edge. “There is certainly a need for rapidly acting antidepressants that are clinically meaningful. So, I do see that psychedelics fit that niche pretty readily.”
Read more